Biomedicines 
Journal Title
- Biomedicines
ISSN
- 2227-9059
Publisher
- MDPI AG
Listed on(Coverage)
| JCR | 2019 |
|---|---|
| SJR | 2017-2019 |
| CiteScore | 2018-2019 |
| SCIE | 2019-2021 |
| CC | 2019-2021 |
| SCOPUS | 2018-2020 |
| DOAJ | 2017-2021 |
OA Info.
| OA |
based on the information
|
|---|---|
| Keywords | biological active substances, quality and safety of biological pharmaceutical products, gene therapy, challenges in administration of biomedicines, development of biomedicines, production of biomedicines |
| Review Process | Blind peer review |
| Journal info. pages | |
| Licences | CC BY |
| Copyrights | Yes |
| DOAJ Coverage |
|
| Subject(s) | Science: Biology (General) |
Active
- Active
based on the information
- SCOPUS:2020-10
Country
- SWITZERLAND
Aime & Scopes
- Aims Biomedicines (ISSN 2227-9059) is an open access journal devoted to research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. The topics include natural bioactive molecules, biologics, biosimilar, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, nano-similars, and nano-biosimilars. The journal is open for publication of studies conducted at the basic science, clinical development and clinical trial stages. Also, publications that address safety, pharmacovigilance regulatory, and ethical issues are welcome. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing special issues of current key topics. The aim of Biomedicines is publishing high quality papers that address the challenges in bringing biological agents or novel targeted strategies through identification, developmentand ultimately to clinical use. Therefore, basic research, comprehensive preclinical studies, clinical development, and clinical trials are all within the scope of the journal. Scope /// Natural Biomedicines Including Marine, Plant, and Animal-Derived Biomedicines; /// Biopharmaceutical Biomedicines: Biologics, and Biosimilar; /// Nanobiotechnological Advances in Biomedicines: Nanomedicine, Nanoscaffold Implants (Synthetic Vascular Graft), Biosensors, Bio imaging, Gene Therapy, Vaccine, Cell Therapy, and Tissue Engineering; /// Biomedicines and Pharmacotherapy: Drug Discovery and Drug Development (Novel Targets) in Various Therapeutic Areas: Cardiovascular, Vascular, Hematology, Oncology, Neurology, Orthopedics, Dermatology, Ophthalmology; /// Pharmacovigilance, Regulatory and Ethical Issues